Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
The European Hematology Association (EHA)
EHA 2016
EHA 2016
CD19 CAR T Cells Induce Potent Responses and Control CNS Leukemia in Relapsed ALL
EHA 2016
,
EHA 2016 – Leukemia
Chimeric antigen receptor (CAR)-modified T cells are emerging as an effective and safe therapy for children and young adults with acute lymphoblastic leukemia (ALL). This study assesses CD19 CAR T cells in pediatric patients with ALL, including patients with a history of central nervous system (CNS) involvement.
Read More ›
Ibrutinib plus Bendamustine and Rituximab (BR) in Previously Treated CLL/SLL: 2-Year Follow-Up Data from the HELIOS Study
EHA 2016
,
EHA 2016 – Leukemia
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, is approved for use as monotherapy in patients with treatment-naïve and relapsed chronic lymphocytic leukemia (CLL). Studies of ibrutinib in combination with other agents are underway. Follow-up data from a large phase 3 study of ibrutinib + BR versus BR in relapsed CLL have now reached the 2-year point.
Read More ›
Acalabrutinib, a Second-Generation BTK Inhibitor, Is Active in Previously Untreated CLL
EHA 2016
,
EHA 2016 – Leukemia
Acalabrutinib is a second-generation inhibitor of Bruton’s tyrosine kinase (BTK) that is currently being evaluated in patients with previously untreated and relapsed chronic lymphocytic leukemia (CLL), as well as other hematologic malignancies. Researchers report phase 1/2 study results for acalabrutinib, including overall response rates, rates of treatment-related lymphocytosis, bleeding risk, and other safety details.
Read More ›
Ibrutinib Results in Robust Clinical Activity and Survival Outcomes in Difficult-to-Treat CLL Populations
EHA 2016
Patients with deletion 17p chronic lymphocytic leukemia (CLL) have aggressive disease and poor outcomes with chemoimmunotherapy. Ibrutinib, a once-daily therapy that inhibits Bruton’s tyrosine kinase, is approved for previously untreated patients with CLL, including patients with deletion 17p. This cross-study analysis of efficacy and tolerability outcomes for ibrutinib reports 2+-year data in this high-risk subset of patients.
Read More ›
Page 3 of 3
1
2
3
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us